{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:30:39Z","timestamp":1782145839629,"version":"3.54.5"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The combination of bortezomib and rituximab was evaluated in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL) and Waldenstr\u00f6m macroglobulinaemia (WM), in a Phase I and later, a randomized Phase II study. In the randomized study, 42 patients with recurrent\/refractory disease received either: bortezomib 1\u00b73\u2003mg\/m<jats:sup>2<\/jats:sup> on days 1, 4, 8 and 11 of a 3\u2010week cycle with rituximab 375\u2003mg\/m<jats:sup>2<\/jats:sup> on day 1 (21 patients) or: bortezomib 1\u00b76\u2003mg\/m<jats:sup>2<\/jats:sup> and rituximab on days 1, 8, 15 and 22 of a 5\u2010week cycle (with rituximab being given only in cycles 1 and 4).Twenty\u2010eight patients were withdrawn (toxicity 16, progression 7, and \u2018patient choice\u2019 5). The main toxicities were neurological, gastro\u2010intestinal and haematological. The overall response rate was 28\/42(67%) and by histology: MCL 11\/19, FL 8\/15, and WM 9\/10. Ten of 28 responding patients remained progression\u2010free at 1\u20133\u00b75\u2003years. Toxicity and efficacy were equivalent between the two groups. The combination has significant toxicity but is effective, particularly in patients with WM.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08340.x","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T07:09:04Z","timestamp":1285744144000},"page":"346-353","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Weekly <i>versus<\/i> twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr\u00f6m macroglobulinaemia"],"prefix":"10.1111","volume":"151","author":[{"given":"Agathoclis","family":"Agathocleous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama","family":"Rohatiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Paul","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,29]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams J.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07836.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8659"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.32.22123"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-233155"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.039"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1098\/rspl.1899.0121"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood.V114.22.933.933","article-title":"Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the phase 2 VERTICAL study","volume":"114","author":"Fowler N.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.V114.22.924.924","article-title":"Bendamustine, bortezomib and rituximab in patients (pts) relapsed\/refractory indolent and mantle cell non\u2010Hodgkin lymphoma (NHL): a multicenter phase II clinical trial","volume":"114","author":"Friedberg J.W.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07775.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001714043"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.164"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3237"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.10.3052"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood.V114.22.1661.1661","article-title":"The VcR\u2010CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405 \u2013 a phase II study of VcR\u2010CVAD with maintenance rituximab for MCL","volume":"2009","author":"Kahl B.S.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.013"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-115170"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V106.11.491.491","article-title":"Phase I\/II trial of bortezomib + CHOP\u2010rituximab in diffuse large B Cell (DLBCL) and mantle cell lymphoma (MCL): phase I results","volume":"106","author":"Leonard J.P.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50065"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1200\/jco.2007.25.18_suppl.8051","article-title":"Schedule of bortezomib administration may be an important determinant of single\u2010agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)","volume":"25","author":"O\u2019Connor O.A.","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24518"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-120972"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood.V114.22.2682.2682","article-title":"CHOP\u2010R + bortezomib as initial therapy for mantle cell lymphoma (MCL)","volume":"114","author":"Ruan J.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_42_1","first-page":"366","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial","volume":"106","author":"San Miguel J.F.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_43_1","first-page":"114","article-title":"Bortezomib added to CVP\u2010R is safe and effective for previously untreated advanced stage follicular lymphoma: a phase II study by the NCIC Clinical Trials Group","volume":"2009","author":"Sehn L.H.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982806"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200105000-00012"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi022"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2511"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.052"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08340.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08340.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:10:37Z","timestamp":1697454637000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08340.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,29]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08340.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08340.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,29]]},"assertion":[{"value":"2010-09-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}